STAT July 10, 2024
Elaine Chen

The Food and Drug Administration rejected Novo Nordisk’s weekly insulin for the treatment of diabetes in a rare setback for the pharmaceutical giant.

The agency has requests related to the manufacturing process and the use of the insulin specifically in type 1 diabetes patients, Novo said in a statement Wednesday. The company, which had submitted an application for the drug for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Christophe Weber, veteran Takeda CEO, to retire next year
FDA warns GLP-1 compounder over safety rules
Metsera, Maze secure combined $415 million in IPOs
Ozempic-Like Drugs May Hold Risks For Surgical Patients, Officials Say
From discovery to delivery: Finding an investment edge in biopharma services

Share This Article